Bassaganya-Riera Josep's Form 4 filing
Landos Biopharma, Inc. (LABP) · filed Mar 2, 2023
- Accession no.
- 0001843575-23-000002
- Filed
- Mar 2, 2023
- Trade date
- Feb 28, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bassaganya-Riera JosepCIK 0001843575 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | common stock | SSaleDisposed | −3,470,736 | –F1 | – | 0 | Indirect | |
| Feb 28, 2023 | common stock | SSaleDisposed | −467,306 | –F1 | – | 0 | Indirect | |
| Feb 28, 2023 | common stock | SSaleDisposed | −496,527 | –F1 | – | 0 | Indirect | |
| Feb 28, 2023 | common stock | SSaleDisposed | −500,000 | –F1 | – | 0 | Indirect | |
| Feb 28, 2023 | common stock | SSaleDisposed | −786,299 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
All of the shares reported as sold on this Form 4 were sold to the issuer for aggregate consideration of $1,888,814.77 in cash plus certain intellectual property rights and other assets, as part of the private transaction described in the issuer's Current Report on Form 8-K filed on February 28, 2023 with the Securities and Exchange Commission.
Referenced by the price of 5 transactions in Table I.